AMN
BEARISH
$20.49
Live
AMN Healthcare Services, Inc. · NYSE
Target $20.86
(+1.8%)
$14.87
52W Range
$30.49
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$787.1M
P/E
N/A
ROE
-35.9%
Profit margin
-10.1%
Debt/Equity
1.37
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
78%
The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.
Key Strengths
Consistently beats earnings estimates with an average surprise of over 90% in the last four quarters
Recent quarterly EPS growth (Q/Q) of +30.0% shows potential operational improvement
Operating margin remains positive at 1.33% despite overall net losses
Gross margin of 29.37% indicates pricing power or cost control at the production level
Price/Sales ratio of 0.29 suggests the market may be pricing in extreme pessimism
Key Risks
Piotroski F-Score of 2/9 signals severe financial weakness and high risk of continued deterioration
Negative profit margin (-10.14%) and ROE (-35.90%) indicate persistent unprofitability and poor capital efficiency
Revenue declining YoY by 7.70%, reflecting shrinking top-line and potential market share loss
High Debt/Equity ratio of 1.37 increases vulnerability to interest rate hikes or downturns
Lack of Altman Z-Score due to missing data raises red flags about balance sheet transparency or solvency risk
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
40
55
30
20
0
AI Verdict
High-risk turnaround candidate with speculative potential but weak fundamentals
Key drivers: Low Piotroski F-Score, Negative earnings and ROE, Recent earnings beat streak, Declining revenue, High leverage
Confidence
75%
Value
40/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Sales ratio (0.29) suggests possible undervaluation relative to sales
Watchpoints
- Forward P/E of 30.31 is high given lack of current profitability
- No Graham Number available due to unprofitability
- Price/Book of 1.22 not supportive given negative ROE
Future
55/100
Ref Growth rates
Positives
- Q/Q Earnings Growth of 319.10% indicates strong recent improvement
- Earnings Growth (YoY) of 321.30% reflects recovery from deep prior-year losses
Watchpoints
- Revenue Growth (YoY) is negative at -7.70%, undermining sustainable future growth
- No clear visibility on earnings inflection given historical volatility
Past
30/100
Ref Historical trends
Positives
- Long history of beating earnings estimates (23 out of 25 quarters)
Watchpoints
- 5Y price return of -72.8% shows prolonged underperformance
- Revenue and earnings peaked in 2022 and have trended downward since
- Persistent net losses over recent years
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio of 1.05 provides minimal short-term liquidity buffer
Watchpoints
- Piotroski F-Score of 2/9 indicates critical financial weakness
- No Altman Z-Score available — potential red flag
- Negative ROE and ROA
- Debt/Equity ratio above 1.0 increases financial risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid (Dividend Yield: N/A)
- Dividend Strength score of 0/100 confirms no income appeal
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$20.49
Analyst Target
$20.86
Upside/Downside
+1.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AMN and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AMN
AMN Healthcare Services, Inc.
Primary
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
MGTX
MeiraGTx Holdings plc
Peer
|
-29.7% | +81.4% | +75.7% | +23.0% | +30.3% | +1.2% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
|
OMDA
Omada Health, Inc.
Peer
|
-43.0% | -43.0% | -43.0% | -48.4% | -11.3% | +4.7% |
|
IART
Integra LifeSciences Holdings Corporation
Peer
|
-85.7% | -83.0% | -43.2% | -25.8% | +3.0% | +3.9% |
AMN
AMN Healthcare Services, Inc.
Primary
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
MGT
MeiraGTx Holdings plc
Peer
5Y
-29.7%
3Y
+81.4%
1Y
+75.7%
6M
+23.0%
1M
+30.3%
1W
+1.2%
ARV
Arvinas, Inc.
Peer
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
OMD
Omada Health, Inc.
Peer
5Y
-43.0%
3Y
-43.0%
1Y
-43.0%
6M
-48.4%
1M
-11.3%
1W
+4.7%
IAR
Integra LifeSciences Holdings Corporation
Peer
5Y
-85.7%
3Y
-83.0%
1Y
-43.2%
6M
-25.8%
1M
+3.0%
1W
+3.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
30.31
PEG Ratio
N/A
P/B Ratio
1.22
P/S Ratio
0.29
EV/Revenue
0.6
EV/EBITDA
7.87
Market Cap
$787.1M
Profitability
Profit margins and return metrics
Profit Margin
-10.14%
Operating Margin
1.33%
Gross Margin
29.37%
ROE
-35.9%
ROA
1.17%
Growth
Revenue and earnings growth rates
Revenue Growth
-7.7%
Earnings Growth
+321.3%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+319.1%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.37
Moderate
Current Ratio
1.05
Good
Quick Ratio
0.94
Poor
Cash/Share
$1.37
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-19
$N/A
2025-11-06
$0.39
+95.2% surprise
2025-08-07
$0.3
+60.9% surprise
2025-05-08
$0.45
+119.3% surprise
Healthcare Sector Comparison
Comparing AMN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-35.9%
This Stock
vs
-88.14%
Sector Avg
-59.3%
(Below Avg)
Profit Margin
-10.14%
This Stock
vs
-16.28%
Sector Avg
-37.7%
(Weaker)
Debt to Equity
1.37
This Stock
vs
2.66
Sector Avg
-48.4%
(Less Debt)
Revenue Growth
-7.7%
This Stock
vs
124.04%
Sector Avg
-106.2%
(Slower)
Current Ratio
1.05
This Stock
vs
4.47
Sector Avg
-76.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | |
|
MGTX
MeiraGTx Holdings plc
|
NEUTRAL | $784.33M | - | -368.2% | -140.3% | $9.63 | Compare |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | Compare |
|
OMDA
Omada Health, Inc.
|
BEARISH | $773.1M | - | -8.7% | -4.9% | $13.12 | Compare |
|
IART
Integra LifeSciences...
|
NEUTRAL | $771.58M | - | -39.9% | -31.6% | $9.9 | Compare |
AMN
AMN Healthcare...
BEARISH
Mkt Cap
$787M
P/E
-
ROE
-35.9%
Price
$20.49
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-15 | GRACE CAROLINE | Chief Executive Officer | Stock Award | 41,131 | - |
| 2026-01-15 | HAGAN MARK CHRISTOPHER | Chief Technology Officer | Stock Award | 10,313 | - |
| 2026-01-15 | LAUGHLIN WHITNEY M. | Officer | Stock Award | 4,488 | - |
| 2026-01-15 | SCOTT BRIAN M | Chief Operating Officer | Stock Award | 8,843 | - |
| 2025-12-15 | SCOTT BRIAN M | Chief Operating Officer | Stock Award | 12,212 | - |
| 2025-11-28 | GRACE CAROLINE | Chief Executive Officer | Stock Award | 8,328 | - |
| 2025-10-15 | HAGAN MARK CHRISTOPHER | Chief Technology Officer | Stock Award | 9,330 | - |
| 2025-10-15 | LAUGHLIN WHITNEY M. | Officer | Stock Award | 4,976 | - |
| 2025-09-15 | LAUGHLIN WHITNEY M. | Officer | Stock Award | 483 | - |
GRACE CAROLINE
Chief Executive Officer
2026-01-15
41,131 shares
HAGAN MARK CHRISTOPHER
Chief Technology Officer
2026-01-15
10,313 shares
LAUGHLIN WHITNEY M.
Officer
2026-01-15
4,488 shares
SCOTT BRIAN M
Chief Operating Officer
2026-01-15
8,843 shares
SCOTT BRIAN M
Chief Operating Officer
2025-12-15
12,212 shares
GRACE CAROLINE
Chief Executive Officer
2025-11-28
8,328 shares
HAGAN MARK CHRISTOPHER
Chief Technology Officer
2025-10-15
9,330 shares
LAUGHLIN WHITNEY M.
Officer
2025-10-15
4,976 shares
LAUGHLIN WHITNEY M.
Officer
2025-09-15
483 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
7 analysts
BMO Capital
2026-01-15
Outperform
Outperform
Citizens
2025-12-19
Market Outperform
Market Outperform
UBS
2025-11-07
Neutral
Neutral
Citizens
2025-11-07
Market Outperform
Market Outperform
Truist Securities
2025-10-13
Buy
Buy
B of A Securities
2025-09-10
Underperform
Underperform
JMP Securities
2025-08-12
Market Outperform
Market Outperform
BMO Capital
2025-08-11
Outperform
Outperform
Past News Coverage
Recent headlines mentioning AMN from our newsroom.
Newest → oldest
No matching news yet.